| Literature DB >> 28609656 |
Detian Yuan1, Shan Huang2, Emanuel Berger3, Lei Liu4, Nina Gross5, Florian Heinzmann6, Marc Ringelhan7, Tracy O Connor1, Mira Stadler2, Michael Meister2, Julia Weber5, Rupert Öllinger5, Nicole Simonavicius8, Florian Reisinger8, Daniel Hartmann4, Rüdiger Meyer9, Maria Reich10, Marco Seehawer6, Valentina Leone8, Bastian Höchst11, Dirk Wohlleber11, Simone Jörs5, Marco Prinz12, Duncan Spalding13, Ulrike Protzer8, Tom Luedde14, Luigi Terracciano15, Matthias Matter15, Thomas Longerich16, Percy Knolle11, Thomas Ried9, Verena Keitel10, Fabian Geisler5, Kristian Unger17, Einat Cinnamon18, Eli Pikarsky19, Norbert Hüser4, Roger J Davis20, Darjus F Tschaharganeh21, Roland Rad5, Achim Weber22, Lars Zender23, Dirk Haller24, Mathias Heikenwalder25.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is a highly malignant, heterogeneous cancer with poor treatment options. We found that mitochondrial dysfunction and oxidative stress trigger a niche favoring cholangiocellular overgrowth and tumorigenesis. Liver damage, reactive oxygen species (ROS) and paracrine tumor necrosis factor (Tnf) from Kupffer cells caused JNK-mediated cholangiocellular proliferation and oncogenic transformation. Anti-oxidant treatment, Kupffer cell depletion, Tnfr1 deletion, or JNK inhibition reduced cholangiocellular pre-neoplastic lesions. Liver-specific JNK1/2 deletion led to tumor reduction and enhanced survival in Akt/Notch- or p53/Kras-induced ICC models. In human ICC, high Tnf expression near ICC lesions, cholangiocellular JNK-phosphorylation, and ROS accumulation in surrounding hepatocytes are present. Thus, Kupffer cell-derived Tnf favors cholangiocellular proliferation/differentiation and carcinogenesis. Targeting the ROS/Tnf/JNK axis may provide opportunities for ICC therapy.Entities:
Keywords: JNK; Kupffer cell; Tnf; cholastasis; intrahepatic cholangiocarcinoma; mitochondrial dysfunction; pro-inflammatory niche; reactive oxygen species; unfolded protein response
Mesh:
Substances:
Year: 2017 PMID: 28609656 DOI: 10.1016/j.ccell.2017.05.006
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743